1-13 of 13
David I. Quinn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

Emmanuel S. Antonarakis, Sumit K. Subudhi, Christopher M. Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason M. Hafron, Helen M. Wilfehrt, Matthew Harmon, Nadeem A. Sheikh, Neal D. Shore, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2426–2434.
https://doi.org/10.1158/1078-0432.CCR-22-3832
Published: 05 July 2023
View article titled, Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Open the PDF for Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

H. Josh Jang, Galen Hostetter, Alexander W. Macfarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Noah M. Hahn, David I. Quinn, Jean-Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2052–2065.
https://doi.org/10.1158/1078-0432.CCR-22-3642
Published: 01 June 2023
View article titled, A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Open the PDF for A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy in another window
Includes: Supplementary data
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View article titled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth J. Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Andrea L. Harzstark, Manish Kohli, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David J. McConkey, Primo N. Lara, Jr, Maha H.A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Jr, Neeraj Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 1967–1973.
https://doi.org/10.1158/1078-0432.CCR-20-3587
Published: 01 April 2021
View article titled, Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Open the PDF for Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) in another window
Journal Articles

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Heather J. Chalfin, Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak, Yen-Lin Chu, Robin Richardson, Rachel Krupa, Amanda K.L. Anderson, Yipeng Wang, Ryan Dittamore, Sumanta K. Pal, Primo N. Lara, Mark N. Stein, David I. Quinn, Seth M. Steinberg, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz, Rene Costello, Jacqueline Cadena, Carlos Diaz, James L. Gulley, William L. Dahut, Howard Streicher, John J. Wright, Jane B. Trepel, Donald P. Bottaro, Andrea B. Apolo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1391–1398.
https://doi.org/10.1158/1078-0432.CCR-20-2891
Published: 01 March 2021
View article titled, Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
Open the PDF for Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer in another window
Includes: Supplementary data
Journal Articles

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival

Emmanuel S. Antonarakis, Eric J. Small, Daniel P. Petrylak, David I. Quinn, Adam S. Kibel, Nancy N. Chang, Erica Dearstyne, Matt Harmon, Dwayne Campogan, Heather Haynes, Tuyen Vu, Nadeem A. Sheikh, Charles G. Drake
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (19): 4662–4671.
https://doi.org/10.1158/1078-0432.CCR-18-0638
Published: 01 October 2018
View article titled, Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival
Open the PDF for Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival in another window
Includes: Supplementary data
Journal Articles

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)

Roberto Pili, David I. Quinn, Hans J. Hammers, Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, Roberto S. Fragomeni, Zsolt Szabo, Alan Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7199–7208.
https://doi.org/10.1158/1078-0432.CCR-17-1178
Published: 30 November 2017
View article titled, Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Open the PDF for Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) in another window
Includes: Supplementary data
Journal Articles

Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer

Stephen V. Liu, Denice D. Tsao-Wei, Shigang Xiong, Susan Groshen, Tanya B. Dorff, David I. Quinn, Yu-Chong Tai, Juergen Engel, Debra Hawes, Andrew V. Schally, Jacek K. Pinski
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6277–6283.
https://doi.org/10.1158/1078-0432.CCR-14-0489
Published: 14 December 2014
View article titled, Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer
Open the PDF for Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr., David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Jr., Maha H.A. Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3028–3034.
https://doi.org/10.1158/1078-0432.CCR-09-3122
Published: 31 May 2010
View article titled, Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Open the PDF for Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer in another window
Journal Articles

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

Primo N. Lara, Jr., Walter M. Stadler, Jeff Longmate, David I. Quinn, Jason Wexler, Marta Van Loan, Przemyslaw Twardowski, Paul H. Gumerlock, Nicholas J. Vogelzang, Everett E. Vokes, Heinz Josef Lenz, James H. Doroshow, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1556–1563.
https://doi.org/10.1158/1078-0432.CCR-05-2074
Published: 06 March 2006
View article titled, A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Open the PDF for A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases in another window
Journal Articles

SU5416 Plus Interferon α in Advanced Renal Cell Carcinoma: A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition

Primo N. Lara, Jr., David I. Quinn, Kim Margolin, Frederick J. Meyers, Jeff Longmate, Paul Frankel, Philip C. Mack, Corinne Turrell, Peter Valk, Jyotsna Rao, Penelope Buckley, Ted Wun, Robert Gosselin, Irina Galvin, Paul H. Gumerlock, Heinz Josef Lenz, James H. Doroshow, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (13): 4772–4781.
Published: 27 October 2003
View article titled, SU5416 Plus Interferon α in Advanced Renal Cell Carcinoma: <subtitle>A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition</subtitle>
Open the PDF for SU5416 Plus Interferon α in Advanced Renal Cell Carcinoma: <subtitle>A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition</subtitle> in another window
Journal Articles

Overexpression of the Cell Cycle Inhibitor p16INK4A in High-grade Prostatic Intraepithelial Neoplasia Predicts Early Relapse in Prostate Cancer Patients

Susan M. Henshall, David I. Quinn, C. Soon Lee, Darren R. Head, David Golovsky, Phillip C. Brenner, Warick Delprado, Phillip D. Stricker, John J. Grygiel, Robert L. Sutherland
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 544–550.
Published: 01 March 2001
View article titled, Overexpression of the Cell Cycle Inhibitor p16<sup>INK4A</sup> in High-grade Prostatic Intraepithelial Neoplasia Predicts Early Relapse in Prostate Cancer Patients
Open the PDF for Overexpression of the Cell Cycle Inhibitor p16<sup>INK4A</sup> in High-grade Prostatic Intraepithelial Neoplasia Predicts Early Relapse in Prostate Cancer Patients in another window
Journal Articles

Cyclin D1 and p16INK4A Expression Predict Reduced Survival in Carcinoma of the Anterior Tongue

Ronaldo J. Bova, David I. Quinn, Jane S. Nankervis, Ian E. Cole, Brian F. Sheridan, Michael J. Jensen, Gary J. Morgan, Christopher J. Hughes, Robert L. Sutherland
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 2810–2819.
Published: 01 October 1999
View article titled, Cyclin D1 and p16<sup>INK4A</sup> Expression Predict Reduced Survival in Carcinoma of the Anterior Tongue
Open the PDF for Cyclin D1 and p16<sup>INK4A</sup> Expression Predict Reduced Survival in Carcinoma of the Anterior Tongue in another window